Drug intelligence / Profile preview

Cyclamax

Development stage
Unknown
Lead developer
Persee Medica
Administration
Oral
01

Overview

**Cyclamax** is a French multi-ingredient dietary supplement and nutraceutical originally developed by Persee Medica for sleep-quality improvement in adults with chronic primary insomnia. The formulation evaluated in the registered randomized, double-blind, placebo-controlled trial NCT00484497 consisted of two soft-gelatin capsules daily for one month and was reported to contain soybean oil, Cade oil labeled as *Cannabis sativa*, *Humulus lupulus* extract, and soybean lecithin. In the 105-participant study, Cyclamax did not produce a statistically significant benefit versus placebo for subjective sleep quality, melatonin measures, or sleep-wake-cycle outcomes. Later retail listings for Cyclamax Sleep + Stress describe a different botanical formulation containing valerian, lemon balm, passionflower, and hop extracts, indicating that the branded product has been reformulated over time. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00484497))

Brand names
CyclamaxCyclamax Sleep + Stress

Beyond the preview

Go deeper on Cyclamax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclamax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call